MCID: PRS017
MIFTS: 18

Prostate Neuroendocrine Neoplasm

Categories: Cancer diseases, Reproductive diseases, Endocrine diseases, Neuronal diseases

Aliases & Classifications for Prostate Neuroendocrine Neoplasm

MalaCards integrated aliases for Prostate Neuroendocrine Neoplasm:

Name: Prostate Neuroendocrine Neoplasm 12 14 69
Neuroendocrine Tumor of the Prostate 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2992
NCIt 47 C5545
UMLS 69 C1335515

Summaries for Prostate Neuroendocrine Neoplasm

MalaCards based summary : Prostate Neuroendocrine Neoplasm, also known as neuroendocrine tumor of the prostate, is related to prostatitis and neuroendocrine tumor. An important gene associated with Prostate Neuroendocrine Neoplasm is SMUG1 (Single-Strand-Selective Monofunctional Uracil-DNA Glycosylase 1). The drugs Somatostatin and Lactitol have been mentioned in the context of this disorder. Affiliated tissues include prostate, breast and bone.

Related Diseases for Prostate Neuroendocrine Neoplasm

Diseases related to Prostate Neuroendocrine Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 prostatitis 9.9
2 neuroendocrine tumor 9.9

Symptoms & Phenotypes for Prostate Neuroendocrine Neoplasm

Drugs & Therapeutics for Prostate Neuroendocrine Neoplasm

Drugs for Prostate Neuroendocrine Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 127)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Somatostatin Approved Phase 4,Phase 2,Phase 3,Phase 1 38916-34-6, 51110-01-1 53481605
2
Lactitol Investigational Phase 4 585-86-4 3871
3 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
4 Hormones Phase 4,Phase 2,Phase 3,Phase 1
5 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
6 lanreotide Approved Phase 2, Phase 3 108736-35-2
7
Octreotide Approved, Investigational Phase 2, Phase 3,Phase 1 83150-76-9 383414 6400441
8 Angiopeptin Phase 2, Phase 3
9 Antineoplastic Agents, Hormonal Phase 2, Phase 3,Phase 1
10 Gastrointestinal Agents Phase 2, Phase 3,Phase 1
11 Liver Extracts Phase 2, Phase 3,Phase 1
12
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
13
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
14
Etoposide Approved Phase 2 33419-42-0 36462
15
Lorazepam Approved Phase 2 846-49-1 3958
16
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
17
nivolumab Approved Phase 2,Phase 1 946414-94-4
18
Trastuzumab Approved, Investigational Phase 2,Phase 1 180288-69-1 9903
19
Olaparib Approved Phase 2 763113-22-0 23725625
20
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
21
Adenosine Approved, Investigational Phase 2 58-61-7 60961
22
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
23
Dabrafenib Approved Phase 2 44462760 44516822
24
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
25
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
26
Osimertinib Approved Phase 2 1421373-65-0 71496458
27
Palbociclib Approved Phase 2 571190-30-2 11431660 5005498 5330286
28
Pertuzumab Approved Phase 2 145040-37-5, 380610-27-5 2540
29 Racepinephrine Approved Phase 2
30
Trametinib Approved Phase 2 871700-17-3 11707110
31
Ethanol Approved Phase 1, Phase 2 64-17-5 702
32
Denosumab Approved Phase 1, Phase 2 615258-40-7
33
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
34
Naltrexone Approved, Investigational, Vet_approved Phase 2 16590-41-3 5360515
35 Tomato Approved, Nutraceutical Phase 1, Phase 2
36
Docetaxel Approved May 1996, Investigational Phase 2,Phase 1 114977-28-5 148124 9877265
37
Cediranib Investigational Phase 2 288383-20-0 9933475
38
Curcumin Investigational Phase 2 458-37-7 969516
39 Albumin-Bound Paclitaxel Phase 1, Phase 2
40 Analgesics Phase 1, Phase 2
41 Analgesics, Non-Narcotic Phase 1, Phase 2
42 Antibodies Phase 1, Phase 2
43 Antibodies, Monoclonal Phase 1, Phase 2
44 Antimitotic Agents Phase 1, Phase 2
45 Antineoplastic Agents, Phytogenic Phase 1, Phase 2
46 Immunoglobulins Phase 1, Phase 2
47 Interleukin-2 Phase 1, Phase 2
48 Peripheral Nervous System Agents Phase 1, Phase 2
49 Etoposide phosphate Phase 2
50 Topoisomerase Inhibitors Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 59)

id Name Status NCT ID Phase Drugs
1 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
2 GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma Completed NCT00495846 Phase 2, Phase 3 Octreotide-LAR, Lanreotide Autogel
3 IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma Unknown status NCT00294476 Phase 2 IVIG
4 Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients Unknown status NCT01134250 Phase 1, Phase 2 F16IL2 in combination with paclitaxel
5 Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers Completed NCT00973882 Phase 2 Carboplatin;Etoposide
6 Effects of Tomato-Soy Juice on Biomarkers in Patients With Prostate Cancer Undergoing Prostatectomy Completed NCT01009736 Phase 1, Phase 2
7 An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155 Completed NCT00818480 Phase 2 YM155
8 Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases Completed NCT00587964 Phase 2
9 Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors Recruiting NCT01803503 Phase 2 Docetaxel;Sunitinib
10 Olaparib With or Without Cediranib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting NCT02893917 Phase 2 Cediranib;Olaparib
11 Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC Recruiting NCT03263650 Phase 2 Cabazitaxel;Carboplatin;Prednisone 5Mg;Olaparib
12 NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma Recruiting NCT02465060 Phase 2 Afatinib;Akt inhibitor AZD5363;Binimetinib;Crizotinib;Dabrafenib;Dasatinib;Defactinib;FGFR Inhibitor AZD4547;Larotrectinib;Osimertinib;Palbociclib;PI3K-beta Inhibitor GSK2636771;Sapanisertib;Sunitinib Malate;Taselisib;Trametinib;Vismodegib;WEE1 Inhibitor AZD1775
13 A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer Active, not recruiting NCT01799278 Phase 2 MLN8237
14 Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Active, not recruiting NCT01466036 Phase 2 Cabozantinib
15 Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of Prostate Cancer Metastatic Castration Resistant (CURTAXEL) Active, not recruiting NCT02095717 Phase 2 Curcumin;Placebo;Taxotere
16 Cabozantinib for Advanced Urothelial Cancer Active, not recruiting NCT01688999 Phase 2 Cabozantinib
17 PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer Not yet recruiting NCT03179410 Phase 2 Avelumab
18 Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma Not yet recruiting NCT03161756 Phase 1, Phase 2 Denosumab;Nivolumab;Ipilimumab
19 A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) Not yet recruiting NCT03207347 Phase 2 Niraparib
20 Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer Terminated NCT01650350 Phase 2 Naltrexone
21 Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma Withdrawn NCT01913691 Phase 2 Ipilimumab
22 Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases Withdrawn NCT00769990 Phase 1, Phase 2
23 Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer Withdrawn NCT01065441 Phase 1, Phase 2
24 Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies Completed NCT00703625 Phase 1 Temsirolimus;Docetaxel
25 Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies Completed NCT00703170 Phase 1 Temsirolimus;Pegylated liposomal doxorubicin
26 Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers Completed NCT00636558 Phase 1 CVA21
27 A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002) Completed NCT00753415 Phase 1
28 A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies Completed NCT00441337 Phase 1
29 ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer Completed NCT00415779 Phase 1 docetaxel;zoledronic acid
30 Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors Completed NCT00003690 Phase 1 alvocidib;carboplatin;cisplatin
31 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
32 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1 tanespimycin
33 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
34 Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors Completed NCT00667641 Phase 1 bortezomib;paclitaxel
35 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1 docetaxel;gemcitabine hydrochloride
36 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
37 131-I-TM-601 Study in Adults With Solid Tumors Completed NCT00379132 Phase 1 131-I-TM-601 (chlorotoxin)
38 Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Completed NCT01522820 Phase 1 Sirolimus
39 Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors Completed NCT00089362 Phase 1 alvespimycin hydrochloride
40 Study of rSIFN-co for Patients With Advanced Solid Tumors Recruiting NCT02464007 Phase 1
41 A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer Recruiting NCT02963051 Phase 1 Copper;Disulfiram;Copper gluconate
42 Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Recruiting NCT01638533 Phase 1 Romidepsin
43 To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Solid Tumors Recruiting NCT03159585 Phase 1 Cyclophosphamide
44 Safety Study of MGA271 in Refractory Cancer Recruiting NCT01391143 Phase 1
45 Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers Recruiting NCT02655822 Phase 1 CPI-444;CPI-444;CPI-444;CPI-444 + atezolizumab
46 Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer Active, not recruiting NCT01480154 Phase 1 Akt Inhibitor MK2206;Hydroxychloroquine
47 A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers Active, not recruiting NCT01460134 Phase 1 CDX-1127;CDX-1127;CDX-1127
48 Treatment With Sandostatin in Patients With Castrate Resistance Prostate Cancer Showing Uptake of 68Ga-DOTATET Not yet recruiting NCT02631616 Phase 1 Somatostatin
49 Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells Terminated NCT01783431 Phase 1 Poly ICLC
50 A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. Completed NCT00428220 sunitinib

Search NIH Clinical Center for Prostate Neuroendocrine Neoplasm

Genetic Tests for Prostate Neuroendocrine Neoplasm

Anatomical Context for Prostate Neuroendocrine Neoplasm

MalaCards organs/tissues related to Prostate Neuroendocrine Neoplasm:

39
Prostate, Breast, Bone, Liver, T Cells, Testes, Brain

Publications for Prostate Neuroendocrine Neoplasm

Variations for Prostate Neuroendocrine Neoplasm

Expression for Prostate Neuroendocrine Neoplasm

Search GEO for disease gene expression data for Prostate Neuroendocrine Neoplasm.

Pathways for Prostate Neuroendocrine Neoplasm

GO Terms for Prostate Neuroendocrine Neoplasm

Sources for Prostate Neuroendocrine Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....